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B CELL lymphomas which often contain the Epstein-Barr virus (EBY) make up the preponderance of 
tumors that collectively have been tcrmed posttransplant 
Iymphoproliferative disordcrs (PTLD). The unusual sus-
ceptibility of PTLD to immune surveillance was first dem-
onstrated in organ allograft recipients following reduction 
(or discontinuance) of immunosuppression I with its atten-
dant risk of precipitating allograft rejection. 
Restoration of tumor surveillance has rccently been 
accomplished in bone marrow transplant recipients with 
PTLD by infusing naive cytotoxic T lymphocytes (CfL) 
obtained from the original donors into the tumor-bearing 
recipients. In these cases the tumors are invariably of donor 
origin, and HLA-restricted effector cells directed against 
viral targets are thought to be the main mediators of tumor 
regressionK~·:1 The unavailability of naive pretransplant re-
cipient leukocytes has precluded direct application of this 
technology to the PTLDs which develop after organ trans-
plantation and which are almost always of recipient origin.4 
However, we report herein an approach whereby the anti-
PTLD activity of the recipient's own cells can be intensified 
in vitro. Reinfusion of these cells has been associated with 
clinical tumor regression in several cases. 
MATERIALS AND METHODS 
Approval from the Institutional Review Board was obtained for 
Iymphokine activated killer (LAK) cell therapy of six patients who 
had PTLD that had incompletely responded to reduced immuno-
suppression, and for one patient who could not tolerate lowering of 
immunosuppressive drugs without the penalrv of rejection. All 
patIents were treated on a compassionate need basis. Peripheral 
blood mononuclear cells were obtained hy leukapheresis and 
cultured in the presence of rhfi:zK~h An average of 2.1 x 10'0 
resultant LAK cells were administered to each patient. Cytotoxic 
activity of cells from both the leukapheresis samples and from the 
final LAK cell preparations was determined hy .. -hour ."Cr release 
assay. PTLD specimens were classified histopathologically as pre· 
viously described. 7 
CLINICAL OUTCOME 
The organ recipients (2 liver. 2 lung, 2 kidney, 1 heart) were 
2 months to 12 years posttransplantation: all but one were 
beyond I year. The PTLD lesions involuted in 4 patients 
with EBY+ PTLD. In two of these patients, this was 
coincident with allograft rejection 3 days and 3 weeks after 
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LAK cell infusion. The rejections were easily controlled 
with prednisone therapy. The antitumor effect was particu-
larly ohvious in a patient whose lower extremity immuno-
blastic lymphoma nodules. which had developed 6 years 
postcardiac transplantation. could be seen to shrink almost 
overnight. 
A third patient with an EBY+ Hodgkins-like lymphoma, 
who had been allowed to reject the allograft 12 years 
posttransplantation. was given LAK cells when residual 
PTLD was found at the time of graft nephrectomy. She 
underwent successful retransplantation l) months later. The 
fourth patient. a double lung recipient whose polymorphic 
PTLD of undetermined clonality originated in the allograft, 
died of pseudomonas pneumonia 41 days postinfusion. No 
tumor was found at the autopsy which was limited to the 
thorax. 
The three surviving patients with EBY+ lesions are well 
with no evidence of residual tumor 12 to 16 months 
post-LAK cell treatment, including the recipient of a sec-
ond renal allograft. 
Three additional organ transplant recipients had EBY-
large cell non-cleaved lymphomas. LAK cell infusion did 
not precipitate rejection in any of these patients. Because 
there was no discernible immediate effect on the tumors, 
chemotherapy (n = 3) or irradiation (n = 1) was started 3 
to 14 days post-LAK-cell infusion. The short time interval 
between cell infusion and the superimposition of other 
therapies made evaluation of the efficacy of LAK cells 
impossible. One patient is alive with residual but stable 
tumor 7 months postinfusion: the other two died after 17 
and 188 days. 
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DISCUSSION 
LAK cell therapv was clearly dfective in four cases of 
PTLD \\ hich had in common the presence of intratumoral 
EBV. Because control of EBY replication in vivo is primar-
ily by EBV -specific CTL'" with a possible accessory role of 
NK cells. Ill. I I the presence of both phenotypes in the LAK 
cell infusate was reassuring. 
Three patients had posttransplant lymphomas in which 
no evidence of EBV was detectable. The underlying cause 
of EBY negative PTLD remains problematic and is likely 
multifactorial. Viruses other than EBV may be operative in 
these tumors, or the lesions in some cases may simply 
represent sporadic lymphomas. Antigenic stimulation by 
allogeneic cells. either of parenchymal or of hematolym-
phoid origin. may also be a cofactor in such cases. Indeed. 
the state of functional tolerance which is associated with 
microchimerism f~ has been shown to be an active process in 
murine modelsl-DKf~ and such subclinical immunostimulation 
may itself provide the environment which predisposes to 
proliferative lymphoid processes. IS 
Although no response to LAK cell treatment was seen in 
the three patients with EBY- tumors. we suggest that the 
early supervention of other inherently immunosuppressive 
antilymphoma therapies following LAK cdl infusion re-
tarded the return of natural surveillance upon which long 
survival presumably depends. Such tumors in our experi-
ence have undergone involution following a period of 
reduced immunosuppression and. indeed. this had been 
demonstrated earlier in the courses of two of the three 
failed LAK ccll cases. For this reason. we believe that LAK 
cells. perhaps repetitively administered. should continue to 
be otfered as a therapeutic option fur EBY PTLD. 
In summary. we conclude that the administration of 
autologous LAK edls appears to be of benefit in PTLD. 
This clrcct is clearly shown in patients with EBV positive 
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tumors. Additional work is necessary to define the mecha-
nism and extent of this etfect. and to clarify the role of LAK 
cell therapy. particularly in patients whose PTLD do not 
have the EBY genome. 
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